Legal & General Group Plc Buys 197,940 Shares of Zevra Therapeutics, Inc. $ZVRA

Legal & General Group Plc increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 26.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 935,677 shares of the company’s stock after buying an additional 197,940 shares during the period. Legal & General Group Plc’s holdings in Zevra Therapeutics were worth $8,243,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock worth $1,148,000 after acquiring an additional 3,827 shares in the last quarter. Wellington Management Group LLP bought a new position in Zevra Therapeutics in the 1st quarter worth about $1,052,000. EntryPoint Capital LLC grew its position in Zevra Therapeutics by 53.8% during the 1st quarter. EntryPoint Capital LLC now owns 40,675 shares of the company’s stock valued at $305,000 after purchasing an additional 14,225 shares during the last quarter. Stonepine Capital Management LLC increased its stake in Zevra Therapeutics by 8.8% during the 1st quarter. Stonepine Capital Management LLC now owns 650,000 shares of the company’s stock valued at $4,868,000 after purchasing an additional 52,300 shares in the last quarter. Finally, Velan Capital Investment Management LP raised its holdings in Zevra Therapeutics by 121.7% in the first quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock worth $4,981,000 after buying an additional 365,000 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on ZVRA. Zacks Research cut shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. JMP Securities lowered their price objective on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Finally, Cantor Fitzgerald decreased their price target on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

Insider Activity at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 19,500 shares of the business’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares in the company, valued at approximately $2,402,213.12. The trade was a 8.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $8.17 on Wednesday. The stock has a market capitalization of $459.95 million, a price-to-earnings ratio of -38.90 and a beta of 1.52. Zevra Therapeutics, Inc. has a 1-year low of $6.19 and a 1-year high of $13.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. The business’s fifty day moving average price is $9.81 and its 200-day moving average price is $9.72.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.The company had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. On average, equities analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.